Wall Street brokerages expect that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) will post ($0.21) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.18). AcelRx Pharmaceuticals also posted earnings of ($0.21) per share in the same quarter last year. The business is scheduled to issue its next quarterly earnings report on Thursday, March 1st.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($1.08) per share for the current fiscal year, with EPS estimates ranging from ($1.14) to ($1.00). For the next financial year, analysts forecast that the business will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.13) to ($0.85). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover AcelRx Pharmaceuticals.
A number of research analysts recently weighed in on ACRX shares. Stifel Nicolaus raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Roth Capital reissued a “buy” rating and issued a $12.50 price objective on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Royal Bank Of Canada set a $6.00 price objective on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. ValuEngine downgraded AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. AcelRx Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $6.83.
In other AcelRx Pharmaceuticals news, Director Mark G. Edwards purchased 30,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were bought at an average cost of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the transaction, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 42,000 shares of company stock worth $89,380. Company insiders own 28.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geller Family Office Services LLC bought a new position in AcelRx Pharmaceuticals in the 3rd quarter worth approximately $460,000. Perennial Advisors LLC acquired a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter worth approximately $138,000. Goldman Sachs Group Inc. acquired a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter worth approximately $530,000. Virtu KCG Holdings LLC grew its holdings in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter worth approximately $319,000. 13.94% of the stock is currently owned by institutional investors.
Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) remained flat at $$2.20 during mid-day trading on Friday. 446,400 shares of the company traded hands, compared to its average volume of 985,300. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75.
WARNING: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/12/06/0-21-eps-expected-for-acelrx-pharmaceuticals-inc-acrx-this-quarter-2.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.